Celgene Stock Return On Asset
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Return On Asset Analysis
Celgene's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Celgene Return On Asset | 0.14 |
Most of Celgene's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Celgene has a Return On Asset of 0.14. This is 101.6% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on asset for all United States stocks is 200.0% lower than that of the firm.
Celgene Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in return on asset category among its peers.
Celgene Fundamentals
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 51.47 % | |||
Current Valuation | 85.34 B | |||
Shares Outstanding | 708.74 M | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 77.62 % | |||
Number Of Shares Shorted | 12.95 M | |||
Price To Earning | 13.31 X | |||
Price To Book | 7.45 X | |||
Price To Sales | 4.54 X | |||
Revenue | 16.35 B | |||
Gross Profit | 14.06 B | |||
EBITDA | 8.42 B | |||
Net Income | 5.27 B | |||
Cash And Equivalents | 9.32 B | |||
Cash Per Share | 13.15 X | |||
Total Debt | 20.1 B | |||
Debt To Equity | 199.90 % | |||
Current Ratio | 3.44 X | |||
Book Value Per Share | 9.22 X | |||
Cash Flow From Operations | 6.35 B | |||
Short Ratio | 3.45 X | |||
Earnings Per Share | 7.32 X | |||
Price To Earnings To Growth | 0.67 X | |||
Number Of Employees | 8.85 K | |||
Beta | 1.41 | |||
Market Capitalization | 77.04 B | |||
Total Asset | 1.11 B | |||
Retained Earnings | 21.79 B | |||
Working Capital | 708.47 M | |||
Current Asset | 849.88 M | |||
Current Liabilities | 141.41 M | |||
Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |